Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrast-enhanced computed tomography

Journal of Gene Medicine

Volumn 14, Issue 9-10, 2012, Pages 590-597

  Penheiter, Alan R ^a   Dingli, David ^a   Bender, Claire E ^a   Russell, Stephen J ^a   Carlson, StephanieK ^a  

^a MAYO CLINIC   (United States)

Author keywords

Iodinated contrast agent; Omnipaque; Oncolytic measles; Pancreatic cancer; Sodium iodide symporter; SPECT CT

Indexed keywords

IOHEXOL; ONCOLYTIC MEASLES VIRUS; ONCOLYTIC VIRUS; SODIUM IODIDE SYMPORTER; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTRAST ENHANCED COMPUTED TOMOGRAPHY; CONTRAST ENHANCEMENT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PANCREAS TUMOR; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS INHIBITION;

ANIMALS; CONTRAST MEDIA; FEMALE; HUMANS; MEASLES VIRUS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIRUSES; SODIUM PERTECHNETATE TC 99M; SYMPORTERS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; X-RAY MICROTOMOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MEASLES VIRUS; MUS; MUS MUSCULUS;

EID: 84868138353     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2670     Document Type: Article

References (33)

1. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007; 15: 651-659.
2. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103: 1641-1646.
3. Dingli D, Kemp BJ, O'Connor MK, et al. Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumour. Mol Imaging Biol 2006; 8: 16-23.
4. Carlson SK, Classic KL, Hadac EM, et al. Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. AJR Am J Roentgenol 2009; 192: 279-287.
5. Jauregui-Osoro M, Sunassee K, Weeks AJ, et al. Synthesis and biological evaluation of [(18)F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter. Eur J Nucl Med Mol Imaging 2010; 37: 2108-2116.
6. Groot-Wassink T, Aboagye EO, Wang Y, et al. Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther 2004; 9: 436-442.
7. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumours. Cancer Res 2000; 60: 2497-2503.
8. Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumour microenvironment. Mol Cancer Res 2006; 4: 61-70.
9. Cheng J, Sauthoff H, Huang Y, et al. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther 2007; 15: 1982-1990.
10. Penheiter AR, Wegman TR, Classic KL, et al. Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. AJR Am J Roentgenol 2010; 195: 341-349.
11. Nagano S, Perentes JY, Jain RK, Boucher Y. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumours. Cancer Res 2008; 68: 3795-3802.
12. Hong CS, Fellows W, Niranjan A, et al. Ectopic matrix metalloproteinase-9 expression in human brain tumour cells enhances oncolytic HSV vector infection. Gene Ther 2010; 17: 1200-1205.
13. Harrison D, Sauthoff H, Heitner S, et al. Wild-type adenovirus decreases tumour xenograft growth, but despite viral persistence complete tumour responses are rarely achieved - deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. Hum Gene Ther 2001; 12: 1323-1332.
14. Heise CC, Williams A, Olesch J, Kirn DH. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoural injection: intratumoural spread and distribution effects. Cancer Gene Ther 1999; 6: 499-504.
15. Jain RK. Delivery of molecular medicine to solid tumours. Science 1996; 271: 1079-1080.
16. Hecht JR, Bedford R, Abbruzzese JL, et al. A phase I/II trial of intratumoural endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003; 9: 555-561.
17. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001; 8: 308-315.
18. Apte MV, Park S, Phillips PA, et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 2004; 29: 179-187.
19. Vonlaufen A, Joshi S, Qu C, et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res 2008; 68: 2085-2093.
20. Choi IK, Lee YS, Yoo JY, et al. Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther 2010; 17: 190-201.
21. Dmitrieva N, Yu L, Viapiano M, et al. Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumour efficacy. Clin Cancer Res 2011; 17: 1362-1372.
22. Ganesh S, Gonzalez Edick M, Idamakanti N, et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumour-bearing mice. Cancer Res 2007; 67: 4399-4407.
23. Kim JH, Lee YS, Kim H, et al. Relaxin expression from tumour-targeting adenoviruses and its intratumoural spread, apoptosis induction, and efficacy. J Natl Cancer Inst 2006; 98: 1482-1493.
24. Tralhao JG, Schaefer L, Micegova M, et al. In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. FASEB J 2003; 17: 464-466.
25. Etoh T, Himeno Y, Matsumoto T, et al. Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res 2003; 9: 1218-1223.
26. Kelly EJ, Hadac EM, Cullen BR, Russell SJ. MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference. PLoS Pathog 2010; 6: e1000820.
27. Nakano K, Todo T, Chijiiwa K, Tanaka M. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol Ther 2001; 3: 431-437.
28. Norman KL, Coffey MC, Hirasawa K, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther 2002; 13: 641-652.
29. Reis CL, Pacheco JM, Ennis MK, Dingli D. In silico evolutionary dynamics of tumour virotherapy. Integr Biol (Camb) 2010; 2: 41-45.
30. Hasegawa K, Pham L, O'Connor MK, et al. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res 2006; 12: 1868-1875.
31. Langfield KK, Walker HJ, Gregory LC, Federspiel MJ. Manufacture of measles viruses. Methods Mol Biol 2011; 737: 345-366.
32. Carlson SK, Classic KL, Hadac EM, et al. In vivo quantification of intratumoural radioisotope uptake using micro-single photon emission computed tomography/computed tomography. Mol Imaging Biol 2006; 8: 324-332.
33. Penheiter AR, Griesmann GE, Federspiel MJ, et al. Pinhole micro-SPECT/CT for noninvasive monitoring and quantification of oncolytic virus dispersion and percentage infection in solid tumours. Gene Ther 2012; 19: 279-287.